Atrial Fibrillation Market is growing at a significant rate during 2020-2027
Atrial Fibrillation |
Atrial fibrillation is a kind of cardiac arrhythmia marked
by an irregular cardiac rhythm produced by a problem with the electrical system
of the heart. One of the most common kinds of heart arrhythmia is atrial
fibrillation. Fluttering heartbeats, irregular pulses, weakness, dizziness, and
weariness are all signs of atrial fibrillation.
According to Coherent Market
Insights, The global Atrial
Fibrillation Market is estimated to account for US$ 40,601.7 Mn in
terms of value by the end of 2027.
The atrial fibrillation market is growing due to a rise in the prevalence of the condition in the older population, technological advancements, and a preference for catheter ablation for cardiac arrhythmia therapy.
When medications are unsuccessful, catheter ablation is used to treat abnormal heart rhythms. It's a low-risk, minimally intrusive therapeutic option for cardiac arrhythmias. The catheter ablation device removes abnormal cardiac tissues that cause irregular heartbeats. In the treatment of cardiac arrhythmias, catheter ablation has a 95.0 percent success rate.
In addition, important firms are developing enhanced catheter ablation for the treatment of atrial fibrillation and the reduction of stroke risk in patients. For example, Abbott Laboratories, a maker of healthcare goods and medical equipment, developed the TactiFlex PAF IDE ablation catheter in August 2020, which is used to treat patients with paroxysmal atrial fibrillation, an irregular heartbeat. It has sensors enabled for patient with atrial fibrillation (AFib) symptoms that cannot be treated with medicine.
In 2019, the new coronavirus (COVID-19) rapidly expanded throughout many nations and regions, having a huge influence on people's lives and the growth of the atrial fibrillation market. It started as a human health issue and has now evolved into a major danger to global trade, economics, and finance. Lockdowns caused by the COVID-19 epidemic delayed manufacture of numerous atrial fibrillation products. Furthermore, with the launch of the COVID-19 vaccine on the market, the number of COVID-19 cases is predicted to decrease in the future. As a result, firms that specialise in atrial fibrillation have reopened at full capacity. By the beginning of 2022, this is predicted to assist expand and regain the atrial fibrillation market share.
After COVID-19 infection cases begin to decline, equipment & machinery producers must focus on protecting their staff, operations, and supply networks to respond to urgent emergencies and establish new methods of working.
Comments
Post a Comment